Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Float Short %

0.23

Margin Of Safety %

4

Put/Call OI Ratio

1.34

EPS Next Q Diff

-0.4

EPS Last/This Y

3.08

EPS This/Next Y

0.36

Price

124.12

Target Price

125.44

Analyst Recom

3

Performance Q

2.77

Relative Volume

1.22

Beta

0.63

Ticker: NVS




20 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-08-15NVS124.211.290.4764720
2025-08-18NVS124.021.490.2052586
2025-08-19NVS124.991.400.9754042
2025-08-20NVS127.221.380.2254710
2025-08-21NVS126.871.370.2955001
2025-08-22NVS126.941.370.1855151
2025-08-25NVS124.991.373.0555163
2025-08-26NVS126.71.380.5655353
2025-08-27NVS126.881.320.9657706
2025-08-28NVS126.521.311.4157745
2025-08-29NVS126.491.312.4457910
2025-09-02NVS126.631.310.0757983
2025-09-03NVS128.241.300.5358226
2025-09-04NVS128.461.290.2858397
2025-09-05NVS129.731.281.5358672
2025-09-08NVS128.641.291.3458948
2025-09-09NVS128.11.302.3959247
2025-09-10NVS126.561.313.1459665
2025-09-11NVS127.681.340.4560188
2025-09-12NVS124.121.344.2160297
DateSymbolLastP/C OIP/C VolTotal OI
20 items Current Page1 of 1




20 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-08-15NVS124.2111.43329.59.02
2025-08-18NVS124.0111.43169.39.02
2025-08-19NVS124.9511.43149.09.02
2025-08-20NVS127.2311.43371.39.02
2025-08-21NVS126.8611.43065.29.02
2025-08-22NVS126.9811.42917.49.02
2025-08-25NVS125.0511.42900.99.02
2025-08-26NVS126.6411.43113.09.02
2025-08-27NVS126.9011.43230.79.02
2025-08-28NVS126.5111.43139.79.02
2025-08-29NVS126.4011.43184.59.02
2025-09-02NVS126.6211.43106.59.02
2025-09-03NVS128.2111.44422.79.02
2025-09-04NVS128.4411.44219.19.02
2025-09-05NVS129.7311.44082.09.02
2025-09-08NVS128.7111.43952.19.02
2025-09-09NVS128.0911.54097.59.02
2025-09-10NVS126.5411.53767.69.02
2025-09-11NVS127.7011.54293.19.00
2025-09-12NVS124.1211.53593.89.00
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
20 items Current Page1 of 1




20 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-08-15NVS0-1.380.23
2025-08-18NVS0-0.390.23
2025-08-19NVS0-0.390.23
2025-08-20NVS0-0.390.23
2025-08-21NVS0-0.390.23
2025-08-22NVS0-0.390.23
2025-08-25NVS0-2.240.23
2025-08-26NVS0-2.240.23
2025-08-27NVS0-2.240.21
2025-08-28NVS0-2.240.21
2025-08-29NVS0-2.240.21
2025-09-02NVS0-2.290.21
2025-09-03NVS0-2.290.21
2025-09-04NVS0-2.290.21
2025-09-05NVS0-2.290.21
2025-09-08NVS0-1.400.21
2025-09-09NVS0-1.400.21
2025-09-10NVS0-1.400.21
2025-09-11NVS0-1.400.23
2025-09-12NVS0-1.400.23
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
20 items Current Page1 of 1

Last Quarter Act. EPS

2.42

Avg. EPS Est. Current Quarter

2.3

Avg. EPS Est. Next Quarter

2.02

Insider Transactions

Institutional Transactions

-1.4

Beta

0.63

Average Sales Estimate Current Quarter

13698

Average Sales Estimate Next Quarter

13590

Fair Value

128.54

Quality Score

96

Growth Score

81

Sentiment Score

42

Actual DrawDown %

4.9

Max Drawdown 5-Year %

-20.4

Target Price

125.44

P/E

17.98

Forward P/E

13.4

PEG

2.21

P/S

4.4

P/B

5.72

P/Free Cash Flow

12.13

EPS

6.91

Average EPS Est. Cur. Y​

9

EPS Next Y. (Est.)

9.35

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

25.65

Relative Volume

1.22

Return on Equity vs Sector %

7.6

Return on Equity vs Industry %

-0.9

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.02

EBIT Estimation

3593.8
Novartis AG
Sector: Healthcare
Industry: Drug Manufacturers - General
Employees: 75883
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease (GvHD). It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in the chronic and/or accelerated phase; Xolair for the treatment of allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Still's disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and other types of functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma for the treatment of genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran), a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.
stock quote shares NVS – Novartis AG Stock Price stock today
news today NVS – Novartis AG stock forecast ,stock prediction 2023 2024 2025
marketwatch NVS – Novartis AG yahoo finance google finance
stock history NVS – Novartis AG invest stock market
stock prices NVS premarket after hours
ticker NVS fair value insiders trading